Increased Soluble PD-1 Predicts Response to Nivolumab plus Ipilimumab in MelanomaJesper Pedersen, Martin R. Jakobsen, Ninna Aggerholm‐Pedersen et al.|Cancers|2022Cited by 22
27 Cytokine signature of PD-1, CXCL10, and TNF-alpha predicts response to nivolumab and ipilimumabJesper Pedersen, Martin R. Jakobsen, Mateo Sokač et al.|Journal for ImmunoTherapy of Cancer|2021Cited by 0